Clinical study of TACE with or without antiviral treatment for hepatitis B virus related unresectable hepatocellular carcinoma

Chinese Journal of Cancer Prevention and Treatment

Volumn 21, Issue 20, 2014, Pages 1617-1622

  Wang, Li Jun ^a   Bu, Wen Zhe ^b,c   Chen, Hua ^b   Li, Jin Peng ^b   Ma, Shuang Shuang ^b,c   Song, Jin Long ^b  

^a SHANDONG MEDICAL IMAGING RESEARCH INSTITUTE   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c UNIVERSITY OF JINAN   (China)

Author keywords

Entecavir; Liver neoplasms; Recurrence; Transarterial chemoembolization

Indexed keywords

ANTIVIRUS AGENT; CHLOROTRIANISENE; ENTECAVIR; HEPATITIS B(E) ANTIGEN;

ADVANCED CANCER; ANTIVIRAL THERAPY; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL RATE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MEDIAN OVERALL SURVIVAL TIME; MEDIAN PROGRESSION FREE SURVIVAL; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SURVIVAL; UNRESECTABLE HEPATOCELLULAR CARCINOMA;

EID: 84916887725     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma [J]. Lancet, 2012, 379(9822): 1245-1255.
2. Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection[J]. JAMA, 2012, 308(18): 1906-1914.
3. Lao XM, Luo G, Ye LT, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma[J]. Liver Int, 2013, 33(4): 595-604.
4. Zhou Y, Zhang Z, Zhao Y, et al. Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a Meta-analysis[J]. World J Surg, 2014, 38(4): 589-596.
5. Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma[J]. Arch Surg, 2011, 146(6): 675-681.
6. Wang X, Zhang C, Zhu Y, et al. Efficacy of 2 years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment[J]. Antiviral Res, 2014, 3(103): 71-77.
7. Liu F, Dan J, Zhang Y, et al. Hepatitis B reactivation after treatment for HBV-related hepatocellular carcinoma: comparative analysis of radiofrequency ablation versus hepatic resection[J]. Zhonghua Gan Zang Bing Za Zhi, 2014, 22(1): 38-42.
8. Lencioni R. New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma[J]. Clin Cancer Res, 2013, 19(6): 1312-1314.
9. Zhong JH, Xiang BD, Gong WF, et al. Comparison of long-term survival of patients with BCLC Stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization[J/CD]. PloS One, 2013, 8(7): e68193.
10. Shaikh T, Cooper C. Reassessing the role for lamivudine in chronichepatitis B infection: a four-year cohort analysis[J]. Can J Gastroenterol, 2012, 26(3): 148-150.
11. Nishikawa H, Nishijima N, Arimoto A, et al. Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy[J]. Oncol Lett, 2013, 6(5): 1213-1218.
12. Yang T, Lu JH, Zhai J, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study[J]. Eur J Surg Oncol, 2012, 38(8): 683-691.
13. Wong GL, Wong VW. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy[J]. World J Gastroenterol, 2013, 19(39): 6515-6522.
14. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma[J]. J Hepato1, 2009, 51(5): 890-897.
15. Peng JW, Lin GN, Xiao JJ, et al. Hepatitis B virus reactivation in hepatocelluIar carcinoma patients undergoing transcatheter arterial chemoembolization therapy[J]. Asia Pac J Clin Oncol, 2012, 8(4): 356-361.
16. Yan Q, Ni J, Zhang GL, et al. Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence[J]. Chin Med J (Engl), 2013, 126(5): 855-859.
17. Li N, Lai EC, Shi J, et al. A comparative study of antiviral therapy after resection of hepatocelluar carcinoma in the immune-active of phase of hepatitis B virus infection[J]. Ann Surg Oncol, 2010, 17(1): 179-185.
18. Chong CC, Wong GL, Lai PB. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 8(20): 6006-6012.
19. Kim JH, Ko SY, Choe WH, et al. Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients[J]. Clin Mol Hepatol, 2013, 19(3): 273-279.
20. Sun P, Yang X, He RQ, et al. Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials[J]. Hepatol Res, 2014, 44(3): 259-269.